Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia

December 11, 2008

The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).

AML is a cancer of myeloid blood cells where abnormal cells accumulate in the bone marrow and interfere with normal blood cell production. Patients with AML typically have a poor prognosis and do not respond well to conventional chemotherapy. Roughly 30 percent of patients diagnosed with MDS will progress to AML.

Dr. Pierre Fenaux, of the University of Paris, presented the updated results from an international phase III trial (AZA-001) which was the first study to show an increased overall survival for higher-risk MDS patients. One-third of patients enrolled in the trial met the World Health Organization (WHO) criteria for AML. This analysis showed that 50 percent of the AML patients who were treated with VIDAZA survived at least two years, compared to only 16 percent of patients treated with CCR.

"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."

The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.

MDS Foundation

---

---

	Medifocus Guidebook on: Acute Myelogenous Leukemia by Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Acute Myelogenous Leukemia is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Acute Myelogenous Leukemia, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Acute Myelogenous Leukemia, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...
	New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia by W. Hiddemann (Editor), R. Mertelsmann (Editor) This book provides a unique overview of the current applications of aclacinomycin A in malignant hematologic disorders, as single-agent therapy or together with other agents in combination regimens. Accounts are given of its action in myelodysplastic syndromes and of its efficacy in acute myeloid leukemias for the latter, one chapter presents the results of single-agent therapy in older patients, while four other studies describe the efficacy of aclacinomycin A combined with conventional or intermediate-dose cytosine arabinoside or etoposide in relapsed or refractory acute myeloid leukemia.
	21st Century Adult Cancer Sourcebook: Adult Acute Myeloid Leukemia (AML), ANLL, Myelogenous or Myeloblastic Leukemia - Clinical Data for Patients, Families, and Physicians by Progressive Management Authoritative information and practical advice from the nation's cancer experts about acute myeloid leukemia (AML) includes official medical data on signs, symptoms, treatment options, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of acute myeloid leukemia. Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. This type of cancer usually gets worse quickly if it is not treated. It is the...
	What You Always Wanted To Know About Adult Acute Myeloid Leukemia (Medical Basic Guides) by Jazzybee Publishing "What You Always Wanted To Know About..." are fully researched, straight-to-the-point, easily understandable and most comprehensive medical ebooks and guides for everybody. Whether you are just interested in the topic of the book or you are directly affected by it, these books can really help you with the information you need. All books including interactive tables-of-contents, this is your step toward new insights and informations. The contents of this book: General Information About Adult Acute Myeloid Leukemia Stages of Adult Acute Myeloid Leukemia Treatment Option Overview Chemotherapy Radiation therapy Stem cell transplant Other drug therapy Treatment Options for Adult Acute Myeloid Leukemia Untreated...
	What You Always Wanted To Know About Childhood Acute Myeloid Leukemia (Medical Basic Guides) by Jazzybee Publishing "What You Always Wanted To Know About..." are fully researched, straight-to-the-point, easily understandable and most comprehensive medical ebooks and guides for everybody. Whether you are just interested in the topic of the book or you are directly affected by it, these books can really help you with the information you need. All books including interactive tables-of-contents, this is your step toward new insights and informations. The contents of this book: General Information About Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies Chronic myelogenous leukemia Juvenile myelomonocytic leukemia Transient myeloproliferative disorder Myelodysplastic syndromes Stages of Childhood Acute Myeloid Leukemia and Other...
	Women's activity, obesity linked to cancer risk: endometrial ca, acute myeloid leukemia.(Women's Health): An article from: Family Practice News by Mitchel L. Zoler (Author) This digital document is an article from Family Practice News, published by International Medical News Group on May 15, 2004. The length of the article is 1013 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Women's activity, obesity linked to cancer risk: endometrial ca, acute myeloid leukemia.(Women's Health) Author: Mitchel L. Zoler Publication: Family Practice News (Magazine/Journal) Date: May 15, 2004 Publisher: International Medical News Group Volume: 34 Issue: 10 Page: 44(2) Distributed by Thomson...
	Childhood and young adult AML: long-term survival favorable.(Hematology)(acute myeloid leukemia)(Clinical report): An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on March 15, 2007. The length of the article is 494 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Childhood and young adult AML: long-term survival favorable.(Hematology)(acute myeloid leukemia)(Clinical report) Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: March 15, 2007 Publisher: Thomson Gale Volume: 40 Issue: 6 Page: 19(1) Article Type: Clinical report Distributed by Thomson...
	21st Century Pediatric Cancer Sourcebook: Childhood Acute Myeloid Leukemia (AML), Myeloid Malignancies, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), TMD, MDS by Progressive Management Authoritative information and practical advice from the nation's cancer experts about childhood Acute Myeloid Leukemia (AML) and related myeloid malignancies, including Chronic Myelogenous leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Transient Myeloproliferative Disorder (TMD), and Myelodysplastic Syndromes MDS, forms of pediatric cancer. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive compilation gives empowered patients, families, caregivers, nurses, and physicians the information they need to understand the diagnosis and treatment of these diseases. Conveniently organized contents include: General Information * Myeloid Leukemias in Children * Classification of Pediatric Myeloid Malignancies...
	New mutations evolve in cancer: acute myeloid leukemia data may aid choice of treatment.(Genes & Cells): An article from: Science News by Laura Sanders (Author) This digital document is an article from Science News, published by Science Service, Inc. on April 23, 2011. The length of the article is 388 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: New mutations evolve in cancer: acute myeloid leukemia data may aid choice of treatment.(Genes & Cells) Author: Laura Sanders Publication: Science News (Magazine/Journal) Date: April 23, 2011 Publisher: Science Service, Inc. Volume: 179 Issue: 9 Page: 11(1) Distributed by Gale, a part of Cengage...
	Chronic Myeloid Leukemia: Biology and Treatment by Angelo M Carella (Editor), George Q Daley (Editor), Connie J. Eaves (Editor), John M Goldman (Editor), Hehlmann Rudiger (Editor) In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest advances in understanding this disease, and the implications those developments have for its management. They explore many topics, including a review of molecular and cellular biology, discussion of conventional chemotherapy and interferon therapy, and recent developments in allografting and autografting. The reader gains not only an incisive view of the biological structure of the disease, but applications of that biology to treatment modalities. Chronic Myeloid Leukemia is ideal for oncologists and other specialists in the field.